Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Research ArticleClinical Studies

Prognostic Value of EGFR Exon-20 Insertions in Czech Patients With Advanced Non-small Cell Lung Cancer

JANA SKRICKOVA, MILOS PESEK, PETR OPALKA, LEONA KOUBKOVA, MILADA ZEMANOVA, MICHAL HRNCIARIK, JIRI BLAZEK, MARTIN SVATON, JANA KREJCI, HELENA COUPKOVA, DANIEL DOLEZAL, TANA TUZOVA, LUBOS HOLUBEC, PARTHIV MAHADEVIA, KRISTINA SANDSTROM, PETER KUNOVSZKI, MAGDA BARINOVA, KAROLINA HURDALKOVA, ONDREJ FISCHER, MARKETA CERNOVSKA and MONIKA BRATOVA
Anticancer Research November 2021, 41 (11) 5625-5634; DOI: https://doi.org/10.21873/anticanres.15378
JANA SKRICKOVA
1Department of Pulmonary Diseases and Tuberculosis, University Hospital Brno, Brno, Czech Republic;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
MILOS PESEK
2Department of Pneumology, University Hospital Pilsen, Pilsen, Czech Republic;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
PETR OPALKA
3Clinic of Pneumology, Bulovka Hospital, Prague, Czech Republic;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
LEONA KOUBKOVA
4Department of Pneumology, Motol University Hospital, Prague, Czech Republic;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
MILADA ZEMANOVA
5Department of Oncology, General University Hospital in Prague, Prague, Czech Republic;
6First Faculty of Medicine, Charles University in Prague, Prague, Czech Republic;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
MICHAL HRNCIARIK
7Department of Pneumology, University Hospital Hradec Kralove, Hradec Kralove, Czech Republic;
8Faculty of Medicine, Charles University in Hradec Kralove, Hradec Kralove, Czech Republic;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
JIRI BLAZEK
2Department of Pneumology, University Hospital Pilsen, Pilsen, Czech Republic;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
MARTIN SVATON
2Department of Pneumology, University Hospital Pilsen, Pilsen, Czech Republic;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
JANA KREJCI
3Clinic of Pneumology, Bulovka Hospital, Prague, Czech Republic;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
HELENA COUPKOVA
9Clinic of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Brno, Czech Republic;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DANIEL DOLEZAL
10Department of Pneumology, Masaryk Hospital Usti nad Labem, Usti nad Labem, Czech Republic;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
TANA TUZOVA
11Department of Oncology, Hospital Jihlava, Jihlava, Czech Republic;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
LUBOS HOLUBEC
12Department of Clinical Oncology, Na Homolce Hospital, Prague, Czech Republic;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
PARTHIV MAHADEVIA
13Janssen Global Medical Affairs, Raritan, NJ, U.S.A.;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
KRISTINA SANDSTROM
14Janssen Global Services, Stockholm, Sweden;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
PETER KUNOVSZKI
15Janssen Global Services, Budapest, Hungary;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: pkunovsz@its.jnj.com
MAGDA BARINOVA
16Institute of Biostatistics and Analyses Ltd., Brno, Czech Republic;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
KAROLINA HURDALKOVA
16Institute of Biostatistics and Analyses Ltd., Brno, Czech Republic;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
ONDREJ FISCHER
17Department of Pulmonary Diseases and Tuberculosis, University Hospital Olomouc, Olomouc, Czech Republic
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
MARKETA CERNOVSKA
2Department of Pneumology, University Hospital Pilsen, Pilsen, Czech Republic;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
MONIKA BRATOVA
1Department of Pulmonary Diseases and Tuberculosis, University Hospital Brno, Brno, Czech Republic;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Background/Aim: Per literature, patients with epidermal growth factor receptor (EGFR) exon-20 insertions respond poorly to tyrosine kinase inhibitors (TKIs). This study analyzed real-world data to examine the prognostic and predictive value of these mutations. Patients and Methods: We conducted a retrospective cohort study using Czech TULUNG Registry data, with data on multiple mutation types, collected in 2011-2020. Results: We analyzed 554 (95.85%) patients with EGFR exon-19 deletions or exon-21 L858R substitutions and 24 (4.15%) patients with exon-20 insertions who received first-line high-value therapies. We summarized clinical characteristics and outcomes in all patients and by cohort. The risk of progression was statistically significantly higher (86%) in the exon-20 insertion cohort compared to the cohort with other mutations. Although not statistically significant, the risk of death was 44% higher in patients with exon-20 insertions. Conclusion: Advanced NSCLC patients with rare EGFR exon-20 insertions have a high risk of progression.

Key Words:
  • EGFR exon-20 insertions
  • NSCLC
  • prognostic values
  • RWE
  • Received September 20, 2021.
  • Revision received October 18, 2021.
  • Accepted October 19, 2021.
  • Copyright © 2021 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.
View Full Text

This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.

patientACCESS

patientACCESS - Patients desiring access to articles
PreviousNext
Back to top

In this issue

Anticancer Research: 41 (11)
Anticancer Research
Vol. 41, Issue 11
November 2021
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Ed Board (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Prognostic Value of EGFR Exon-20 Insertions in Czech Patients With Advanced Non-small Cell Lung Cancer
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
12 + 1 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Prognostic Value of EGFR Exon-20 Insertions in Czech Patients With Advanced Non-small Cell Lung Cancer
JANA SKRICKOVA, MILOS PESEK, PETR OPALKA, LEONA KOUBKOVA, MILADA ZEMANOVA, MICHAL HRNCIARIK, JIRI BLAZEK, MARTIN SVATON, JANA KREJCI, HELENA COUPKOVA, DANIEL DOLEZAL, TANA TUZOVA, LUBOS HOLUBEC, PARTHIV MAHADEVIA, KRISTINA SANDSTROM, PETER KUNOVSZKI, MAGDA BARINOVA, KAROLINA HURDALKOVA, ONDREJ FISCHER, MARKETA CERNOVSKA, MONIKA BRATOVA
Anticancer Research Nov 2021, 41 (11) 5625-5634; DOI: 10.21873/anticanres.15378

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Prognostic Value of EGFR Exon-20 Insertions in Czech Patients With Advanced Non-small Cell Lung Cancer
JANA SKRICKOVA, MILOS PESEK, PETR OPALKA, LEONA KOUBKOVA, MILADA ZEMANOVA, MICHAL HRNCIARIK, JIRI BLAZEK, MARTIN SVATON, JANA KREJCI, HELENA COUPKOVA, DANIEL DOLEZAL, TANA TUZOVA, LUBOS HOLUBEC, PARTHIV MAHADEVIA, KRISTINA SANDSTROM, PETER KUNOVSZKI, MAGDA BARINOVA, KAROLINA HURDALKOVA, ONDREJ FISCHER, MARKETA CERNOVSKA, MONIKA BRATOVA
Anticancer Research Nov 2021, 41 (11) 5625-5634; DOI: 10.21873/anticanres.15378
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Patients and Methods
    • Results
    • Discussion
    • Conclusion
    • Acknowledgements
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • A Novel Filtration Membrane for Clustered Circulating Tumor Cell Extraction: A Prospective Feasibility Study
  • Atezolizumab for EGFR-mutated Non-small Cell Lung Cancer Patients: An Observation Study in Ibaraki Group (ATTENTION-IBARAKI)
  • Early Phase Persistent Changes in the White Blood Cell Fraction in Patients With Advanced Urothelial Carcinoma Treated With Pembrolizumab: A Multicenter Retrospective Study
Show more Clinical Studies

Similar Articles

Keywords

  • EGFR exon-20 insertions
  • NSCLC
  • prognostic values
  • RWE
Anticancer Research

© 2023 Anticancer Research

Powered by HighWire